Galderma Group AG (SWX:GALD)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 33.66B +39.9% |
| Revenue (ttm) | 4.16B +18.0% |
| Net Income | 486.08M +165.4% |
| EPS | 2.05 +166.0% |
| Shares Out | 234.57M |
| PE Ratio | 70.14 |
| Forward PE | 39.84 |
| Dividend | 0.35 (0.24%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 472,411 |
| Average Volume | 2,449,726 |
| Open | 146.40 |
| Previous Close | 143.50 |
| Day's Range | 145.00 - 148.30 |
| 52-Week Range | 72.70 - 170.10 |
| Beta | -0.11 |
| RSI | 50.20 |
| Earnings Date | Mar 5, 2026 |
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 19... [Read more]
Full Company ProfileFinancial Performance
In 2025, Galderma Group AG's revenue was $5.24 billion, an increase of 18.04% compared to the previous year's $4.44 billion. Earnings were $613.00 million, an increase of 165.37%.
Financial numbers in USD Financial StatementsNews
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, will present the latest updates on its innovations across its broad portfolio at the 2026 American A...
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hollow...
Galderma Publishes Invitation and Agenda for Its 2026 Annual General Meeting
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX: GALD), the pure-play dermatology category leader, today published the invitation and agenda for its 2026 Annual General Meeting (AGM), which ...
AMWC 2026: Galderma Showcases Category‑leading Innovation With a Comprehensive Portfolio and Holistic, Future‑focused Aesthetic Strategies
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) will present nine abstracts at the Aesthetic & Anti‑Aging Medicine (AMWC) World Congress 2026 in Monaco, showcasing innovative and robust scient...
Galderma To Repurchase 1.6 Mln Shares For About CHF 232 Mln In Accelerated Bookbuild Transaction
(RTTNews) - Galderma Group AG (GALD.SW, GDERF), a Swiss-based, pure-play dermatology company, on Thursday on Wednesday agreed to repurchase 1.6 million shares.
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per sha...
Galderma Completes Successful Placement of EUR 500 Million Eurobond
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SWX:GALD): NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW...
Galderma Introduces Cetaphil AM/PM Antioxidant Serums, a New Science-Driven Defense and Recovery System for Sensitive Skin
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is launching its new Cetaphil AM/PM Antio...
Galderma Group AG (GDERF) Full Year 2025 Earnings Call Highlights: Record Sales and Strategic ...
Galderma Group AG (GDERF) Full Year 2025 Earnings Call Highlights: Record Sales and Strategic Growth Amid Market Challenges
Galderma gives better than expected 2026 guidance, shares rise
Shares of Swiss skincare company Galderma opened higher on Thursday after it reported 17.7% growth in full-year net sales and gave an upbeat guidance for 2026.
Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency1, and Core EBITDA2 of 1.211 billion USD, Growing 18.9% at Constant Currency
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 mill...
Galderma's Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-...
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company's Position at the Forefront of Injectable Aesthetics
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA...
Galderma Announces Appointment of New Chief Financial Officer
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the appointment of Luigi La Corte as Chief Financial Officer (CFO), effectiv...
We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra's Regenerative Properties
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today unveiled We Are All Sculptra, a unique program designed to capture the clinical impact of Scul...
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic ac...
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe ...
Galderma Tackles Menopause-related Skin Changes With Global Survey and Clinical Trial Inclusivity
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) has unveiled findings from a global survey of peri- and post-menopausal women from nine countries exploring the impact of menopause on the skin ...
Galderma Unveils ‘Wake Up To Restylane', Underscoring Restylane as the Ideal Hyaluronic Acid Treatment for Always-On Natural Beauty
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, has launched ‘Wake Up To Restylane', a global campaign that showcases Restylane as an everyday beaut...
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry's Broadest Injectable Aesthetics Portfolio
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromod...
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirmin...
TOXINS 2026: Clinical Updates on Galderma's Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain f...
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and s...
L'Oreal Doubles Stake in Swiss Skincare Company Galderma
Financial terms weren't disclosed., but the package of about 24 million Galderma shares would be valued at $4.85 billion based on Friday's closing price.
EQT agrees to sale of shares in Galderma Group AG to L'Oréal S.A.
C. 24 million shares to be sold STOCKHOLM , Dec. 8, 2025 /PRNewswire/ -- Further to previous announcements, an affiliate of the funds known as EQT VIII ("EQT") is pleased to announce it has signed an ...